Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

MRI Global Kansas City MO 64110 USA

UEI: SLED_5435404E2610A6D7

MRI Global Kansas City MO 64110 USA is a federal contractor, registered under UEI SLED_5435404E2610A6D7. It has been awarded $45,000,000 in federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology). Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_5435404E2610A6D7

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

AI Capability Profile

MRI Global provides specialized laboratory services focused on biomedical research and controlled exposure studies. Their technical expertise includes conducting controlled exposures of various animal species to chemical agents to support medical countermeasures and preparedness. The company suppor...

Key Performance Metrics

Awards Count

1

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Department Of Health And Human Services$45.0M100%

Awards by NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)$45.0M100%

Awards by Agency Over Time

Awards by Place of Performance

Compete with MRI Global Kansas City MO 64110 USA

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for MRI Global Kansas City MO 64110 USA

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Join 750+ contractors already using CLEATUS

Open opportunities in MRI Global Kansas City MO 64110 USA's top NAICS codes and agencies

Quantitative Analysis of Longitudinal MR Images

Solicitation # 75N98027R00005

Solicitation 75N98027R00005 is a Sources Sought notice issued by the National Institute on Aging (NIA) to identify qualified companies capable of performing quantitative analysis of longitudinal Magnetic Resonance (MR) images. The project supports the Baltimore Longitudinal Study of Aging (BLSA) by processing 300 newly acquired MR datasets to characterize brain aging trajectories and identify predictors of cognitive decline and Alzheimer’s disease. The selected contractor will provide specialized, non-commercial services to deliver global and regional tissue volumes, lesion quantification, and machine learning-derived scores, such as SPARE-AD, while ensuring longitudinal consistency with data acquired since 1994. The anticipated contract will be a firm fixed price award with a period of performance of one year. Key deliverables include quantitative volumetric results, intermediate processing files, and registration maps for PET overlay, submitted every six months, concluding with a final report. Technical requirements emphasize the use of established image analysis tools and adherence to FISMA/FedRAMP-aligned data security controls to protect participant confidentiality. Interested respondents must submit a capability statement by November 9, 2026, to Contract Specialist Sneha Singh. The submission must be limited to ten pages and include the company's Unique Entity ID, NAICS code 541714, professional qualifications of personnel, and any applicable GSA schedules or government-wide acquisition contracts. Small businesses are encouraged to respond to this market research effort to help the government determine the appropriate acquisition method.

National Institutes Of Health Olao

POSTED

DEADLINE

Q--AMPLICON SEQUENCING SERVICES

Solicitation # 140G0226Q0047

The Department of the Interior, through the USGS OAG Denver Acquisition Branch, is soliciting quotations for a Blanket Purchase Agreement (BPA) to provide next-generation amplicon sequencing services for the Michigan Bacteriological Research Laboratory. The agreement has a not-to-exceed value of $250,000 over a five-year period of performance from September 17, 2026, to September 16, 2031. The scope of work includes non-personal services such as library preparation for 16S V4 amplicon sequencing, library pooling, and sequencing using Illumina MiSeq or AVITI platforms to support research on bacterial pathogens, antibiotic resistance, and microbial ecology. Key deliverables include demultiplexed raw data and reporting metrics, with a required delivery turnaround of 60 business days from sample receipt. Award decisions will be based on technical and priced factors, with non-priced factors carrying significantly more weight. Technical evaluations will focus on the contractor's on-site equipment, personnel experience, quality control procedures, business establishment, and a capabilities narrative. Offerors must also provide two customer references from the last five years. The contract is subject to various federal regulations, including specific security prohibitions regarding certain telecommunications equipment and the requirement for electronic invoicing through the Invoice Processing Platform System. Quotations are due by November 5, 2026, and must be submitted via email to the primary point of contact.

Ofc Of Acquisition Grants-Denver

POSTED

DEADLINE

ARPA-H Emerging Health Innovators (EHI) Initiative

Solicitation # ARPA-H-SOL-26-150

The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, seeks to identify and engage early-career investigators to develop cutting-edge biomedical, health, and community-engaged research. This opportunity is open to researchers from academic, nonprofit, and industry organizations, provided the Principal Investigator is within eight years of completing their first terminal degree. The initiative covers 16 specific topic areas, including AI in life sciences, brain stimulation, and human tissue platforms. Awards are issued as Other Transaction (OT) agreements, which are not subject to the Federal Acquisition Regulation (FAR). The selection process is a two-step submission involving an initial anonymized Solution Summary and a subsequent Full Proposal for selected candidates. Successful awards have a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a 24-month base period capped at 700,000 dollars and an optional 12-month Director's Award period capped at 350,000 dollars. Payments are structured as fixed payments triggered by the completion of 12 discrete, measurable milestones. Full proposals are evaluated based on technical merit, innovativeness, feasibility, alignment with the ARPA-H mission to accelerate health outcomes, and price reasonableness. Administrative requirements include mandatory registration in SAM.gov and the use of the ARPA-H Solutions site for all submissions. Proposers must adhere to strict formatting templates for technical and management proposals, milestone schedules, and national policy requirements, including disclosures regarding organizational conflicts of interest and research security. Performance is monitored through a formal inspection and acceptance process where the government reviews deliverables within 14 calendar days. The tentative award start date is June 30, 2027, with full proposals due by February 10, 2027.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

Rpo East (36C24E)

POSTED

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

Rpo East (36C24E)

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)

Solicitation # W911SR-26-R-HEAL

The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.

POSTED

DEADLINE

AJ12--Development/Production - Kidney GEC-Specific AAV Vector

Solicitation # 36C24E27Q0009

The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.

Rpo East (36C24E)

POSTED

DEADLINE

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Barley Net Blotch Initiative (BNBI) Program 2 – Host and pathogen genetics

Solicitation # PROC-9177507

The Grains Research and Development Corporation is seeking a partner to deliver Program 2 of the Barley Net Blotch Initiative, a five-year national effort to combat the significant economic threat of net blotch in Australian barley. This specific program focuses on host and pathogen genetics to fast-track the development of durable host resistance. Key objectives include providing breeder-deployable validated markers, characterizing resistance sources, conducting pathogenic genomics research, establishing a durability risk-assessment framework, and assessing the feasibility of genome-editing. This solicitation, identified as PROC-9177507, was posted on October 19, 2026, with a response deadline of March 4, 2027. The project is part of a broader strategy involving pathogen surveillance and integrated disease management to reduce the estimated 122 million dollar annual loss caused by yield decreases and grain quality downgrades. Performance of the contract will span multiple major Australian cities, including Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, and Hobart.

Grains Research and Development Corporation

POSTED

DEADLINE

Pre-Clinical Models of Infectious Diseases

Solicitation # 75N93027R00003

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.

National Institutes Of Health Niaid

POSTED

DEADLINE

in about 1 month

Alternative Protein Technologies for Military Field Feeding

Solicitation # W911QY27ALTPROTEINS

The US Army Combat Capabilities Development Command Soldier Center is seeking information from Massachusetts-based offerors to identify innovative alternative protein technologies for integration into military rations. The objective is to enhance food supply chain resilience and provide nutrient-dense, lightweight food options for warfighters. Areas of interest include fermentation and biomanufacturing processes, innovative product development for shelf-stable rations, consumer research for military acceptability, and the optional provision of GRAS-certified food samples. Specifically, the government is excluding any solutions involving cell-cultured, lab-grown meat, or insect proteins, focusing instead on technologies between TRL 4 and 6. This is a Sources Sought Announcement for market research purposes and not a formal solicitation or a promise of future funding. Interested parties must submit a BAA preproposal by November 23, 2026, including a technical approach, past performance, and a rough order of magnitude cost estimate. Submissions must be sent via email to the designated points of contact and include the offeror's business size, NAICS code, and CAGE code to verify their Massachusetts location.

W6QK Acc-Apg Natick

POSTED

DEADLINE

USDA SBIR/STTR Topic 8.2 — Plant Production and Protection - Biology

Solicitation # USDA-NIFA-TOPIC-8.2

The USDA National Institute of Food and Agriculture is soliciting proposals under Topic 8.2 for Plant Production and Protection - Biology. This initiative focuses on advancing crop production and protection through the development of innovative plant breeding methods, diagnostic technologies for diseases, and the creation of new food and non-food crop plants. Research efforts are directed toward improving plant characteristics to mitigate biotic and abiotic stresses, developing new genotypes for commercial applications, and creating tools to support the health of natural and domesticated pollinators. This opportunity is a total small business set-aside under the SBIR/STTR mandate, restricting eligibility to companies with fewer than 500 employees. Managed by the United States Department of Agriculture, the program is led by Dr. Christopher Philips. Interested parties can find further details and application guidelines through the NIFA website.

National Institute of Food and Agriculture

POSTED

DEADLINE

Artificial Blood and Medical Consumable InnovationThe Artificial Blood and Medical Consumable Innovation subcontract supports the Defense Advanced Research Projects Agency within the Department of Defense. The scope of work involves providing innovative medical consumables and conducting biochemical research specifically focused on the development of artificial blood for prime contractors on DARPA Biological Technologies Office projects. The contractor is responsible for engineering scalable manufacturing processes for these consumables using sterile manufacturing facilities and bio-reactors. Key deliverables include the production of artificial blood prototypes and the implementation of scalable medical consumable solutions. This effort falls under NAICS code 541714, with a response deadline set for November 15, 2026.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE